Scientists at Sanaria and Seattle Children's Research Institute's Center for Global Infectious Disease Research (CGIDR) have unveiled a groundbreaking malaria vaccine, Sanaria® PfSPZ-LARC2 Vaccine, ...

Scientists at Sanaria and Seattle Children’s Research Institute’s Center for Global Infectious Disease Research (CGIDR) have unveiled a groundbreaking malaria vaccine, Sanaria® PfSPZ-LARC2 Vaccine, ...

The anti-malarial mAbs evaluated in trials in malaria-endemic regions target the P. falciparum sporozoite—the life stage of the parasite that is transmitted from mosquitoes to people. By binding ...

Partial resistance to artemisinin, the recommended treatment for Plasmodium falciparum malaria, occurred in Ugandan children with severe disease who were treated with the drug, and some treated ...

Scientists at Sanaria and Seattle Children's Research Institute's Center for Global Infectious Disease Research (CGIDR) have unveiled a groundbreaking ...

Plasmodium falciparum. There are obvious questions that come to mind, including the simplest, why did it take so long for a vaccine to be developed for a disease that kills more than 250,000 ...

1) The malaria parasite Plasmodium falciparum expresses the protein PfEMP1 on the surface of erythrocytes to adhere the cells to blood vessel walls and escape clearance by the spleen. 2) PfEMP1 can be ...

The malaria parasite, Plasmodium falciparum, however, is an entirely more challenging pathogen because it is such a large and complex organism compared to a virus. At the Proteo-Science Center at ...

Over 60% of the samples analyzed were positive for malaria. Malaria, typically caused by Plasmodium falciparum, is quite common in the DRC, with approximately 12% of all cases and deaths worldwide ...

Of the handful of parasite species that cause malaria in humans, Plasmodium falciparum is the deadliest. When an infected female Anopheles mosquito feeds on a person, it injects saliva into the ...

Plasmodium falciparum has shown an ability to evade everything we throw at it, most recently artemisinin-based combination therapies, today’s front-line treatment. Natalie Slivinski This person does ...

Ph.D. in Natural Sciences, Georgetown University, Washington D.C. Masters Thesis: 1988 "Detection of antibodies to a defined malarial antigen in humans exposed to Plasmodium falciparum" Ph. D. Thesis: ...